Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Both therapies exhibit favorable and comparable safety profiles, primarily characterized by transient gastrointestinal adverse events (22, 25)
[2] [3] 73m), it's important to note that the glucose-lowering effect diminishes at lower eGFR levels, even though cardiovascular and renal benefits may persist
These results have been successfully replicated in studies using other animal models
Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist
doi:10.1038/s41392-023-01481-w Neumaier F, Zlatopolskiy BD, Neumaier B
